Brussels, Belgium | Yesterday Enabel signed Cooperation Agreements with the Université Libre de Bruxelles (ULB) and the Federal Agency for Medicines and Health Products (FAMHP). This allows the Belgian development agency to use the expertise of both organisations in partner countries in several sectors.
ULB will continue to support Enabel’s health projects in partner countries in the area of biotechnology. In the context of equitable access to medicines and vaccines, ULB will be mobilised to strengthen the personnel involved in their production in Africa. The establishment of monitoring systems and learning processes, the development of scientific support and capitalising on ongoing projects, as well as support in educational projects in partner countries will be further strengthened.
“With this agreement, we want to use our existing competences and strengthen ongoing initiatives. But we are also going to explore future financing possibilities”, states Jean Van Wetter, Managing director of Enabel.
The agreement with the FAMHP will enable Enabel’s partner countries to set up an appropriate regulatory framework to ensure the quality, safety and efficacy of medicines and health products for both human and veterinary use in clinical development and on the market. However, cooperation with the FAMHP also means that scientific advice can be provided for all Enabel’s health projects in the partner countries, including advice on procedures, fees and regulations. In the short term, the FAMHP will provide support to the regulatory sector for the marketing of vaccines and medicines in Senegal and Rwanda.
Since the corona pandemic the Belgian development agency has been working on fairer access to vaccines in Africa, as a bridge builder between the future producing countries such as Senegal and various actors working on this in Belgium, such as FAMHP, Sciensano and other public services.